Commentary on “Positron Emission Tomography in Lymphoma: Comparison with Computed Tomography and Gallium-67 Single Photon Emission Computed Tomography Imaging”
- 1 June 2000
- journal article
- editorial
- Published by Elsevier in Clinical Lymphoma
- Vol. 1 (1) , 75-76
- https://doi.org/10.1016/s1526-9655(11)70192-0
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Positron Emission Tomography in Lymphoma: Comparison with Computed Tomography and Gallium-67 Single Photon Emission Computed TomographyClinical Lymphoma, 2000
- 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomasAnnals of Oncology, 2000
- The role of positron emission tomography (PET) in the management of lymphoma patientsAnnals of Oncology, 1999
- Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-typeAnnals of Oncology, 1999
- Whole-Body Positron Emission Tomography Using18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin’s Disease and Non-Hodgkin’s Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan ImagingBlood, 1999
- Positron Emission Tomography (PET) for Staging and Evaluation of Response to Treatment in Patients with Hodgkin's DiseaseLeukemia & Lymphoma, 1999
- Whole-body 18F-FDG PET for the evaluation of patients with Hodgkinʼs disease and non-Hodgkinʼs lymphomaNuclear Medicine Communications, 1999
- Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucoseEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996